Number of women reporting adverse events ‐ not reported · women with urinary incontinence
It is very uncertain whether PFMT added to drug therapy changes number of women reporting adverse events compared with drug therapy alone (very low certainty).
1 finding from 1 review
Incontinence‐specific quality of life · women with urinary incontinence
1 finding from 1 review
General health status evaluation e.g. Short Form (SF)‐36 ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of drug intake, end of treatment · adults with stimulant use disorder
1 finding from 1 review
Receipt of treatment for hypoglycaemia during initial hospital stay (investigator‐defined, any treatment ‐ oral dextrose gel, intravenous dextrose, or other drug therapy) during initial hospital stay (yes/no) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in receipt of treatment for hypoglycaemia during initial hospital stay… compared with placebo (moderate certainty).
1 finding from 1 review
Drug (non‐alcohol) use Polydrug consumption levels measured by Opiate Treatment Index (OT) · people with both severe mental illness and substance misuse
1 finding from 1 review
Drug (non‐alcohol) use Polydrug consumption levels measured by Opiate Treatment Index (OT) · people with both severe mental illness and substance misuse
1 finding from 1 review
Bradycardia (requiring pharmacological or pacemaker treatment during the period of study drug administration) · adults undergoing cardiac surgery
Alpha‐2 adrenergic agonists probably leads to higher bradycardia (requiring pharmacological or pacemaker treatment during… compared with control (moderate certainty).
1 finding from 1 review
Hypotension (requiring treatment with inotropes or vasopressors during the period of study drug administration) · adults undergoing cardiac surgery
Alpha‐2 adrenergic agonists showed no clear difference in hypotension (requiring treatment with inotropes or vasopressors… compared with control (low certainty).
1 finding from 1 review
Bradycardia (requiring pharmacological or pacemaker treatment during the period of study drug administration) · adults undergoing non‐cardiac surgery
1 finding from 1 review
Hypotension (requiring treatment with inotropes or vasopressors during the period of study drug administration) · adults undergoing non‐cardiac surgery
1 finding from 1 review
Treatment failure within 4 weeks ‐ current drugs only · exacerbations of COPD
Antibiotics may leads to lower treatment failure within 4 weeks ‐ current drugs only compared with placebo (low certainty).
1 finding from 1 review
Treatment failure within 4 weeks ‐ current drugs only ‐ inpatient · exacerbations of COPD
Antibiotics showed no clear difference in treatment failure within 4 weeks ‐ current drugs only ‐ inpatient compared with placebo (moderate certainty).
1 finding from 1 review
Treatment failure within 4 weeks ‐ drugs not currently used ‐ ICU · exacerbations of COPD
Antibiotics probably leads to lower treatment failure within 4 weeks ‐ drugs not currently used ‐ ICU compared with placebo (moderate certainty).
1 finding from 1 review
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: steroid‐resistant rejection episodes
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode
It is very uncertain whether antibody (T cell) changes treatment adverse events: fever, chill, or malaise after drug… compared with steroid (stratified by antibody type) (very low certainty).
1 finding from 1 review
Drug or alcohol use, or both following treatment completion ‐ Group‐based intervention As assessed by the ASI, TLFB or CIDI. High scores indicate greater symptom severity · Individuals with post‐traumatic stress disorder and comorbid substance use disorder
1 finding from 1 review
Drug or alcohol use, or both following treatment completion ‐ Individual‐based intervention · Individuals with post‐traumatic stress disorder and comorbid substance use disorder
1 finding from 1 review
Intervention not reported
Drug or alcohol use, or both following treatment completion As assessed by the TLFB or CIDI. High scores indicate greater symptom severity · Individuals with post‐traumatic stress disorder and comorbid substance use disorder
1 finding from 1 review